Single sample, urine albumin/creatinine ratio (mg/mmol)1 | Timed overnight collection, urine albumin (µg/min) | 24-hour collection, urine albumin (mg/24 hours) | |
---|---|---|---|
Normal | <3 | <20 | <30 |
Moderately increased albuminuria (previously microalbuminuria') | 3-30 | 20-200 | 30-300 |
Severely increased albuminuria (previously macroalbuminuria' or proteinuria') | >30 | >200 | >300 |
1 Reference values vary between laboratories. The ranges given in the table allow for inaccuracy related to the sample or the assay methods. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Classification of chronic kidney disease by estimated glomerular filtration rate (eGFR)
Epidemiology
PreventionChoice of Antihypertensive Drug in the Diabetic Patient from Prognostic Point of View, Glycaemic Control for Slowing the Progression of Microvascular Complications in Diabetes Mellitus, Protein Restriction in Diabetic Renal Disease, Statins for Improving Renal Outcomes, Reducing Cardiovascular Events by Multifactorial Intervention in Patients with Type 2 Diabetes, , ACE Inhibitors and Angiotensin II Receptor Blockers for Diabetics with Microalbuminuria, Sglt-2 Inhibitors and GLP-1 Agonists for Diabetes and Chronic Kidney Disease
Diagnosis of diabetic kidney disease
Measuring albuminuria
Treatment of hyperglycaemia
Treatment of hypertensionACE Inhibitors and Angiotensin II Receptor Blockers for Diabetics with Microalbuminuria, Antihypertensive Agents for Preventing Diabetic Kidney Disease, Choice of Antihypertensive Drug in the Diabetic Patient from Prognostic Point of View
Diet
Aims
Diet therapy in practice
Indications for a specialist consultation
Drug therapy in diabetic kidney diseaseSglt-2 Inhibitors and GLP-1 Agonists for Diabetes and Chronic Kidney Disease
Patients with type 2 diabetes
Antidiabetic drugs and renal failure. eGFR levels ≥ 60 ml/min require no dose adjustment.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 No dose adjustment is required due to renal failure but the drug is not recommended for patients with renal failure because of the likelihood of increased oedema. 2 No dose adjustment if eGFR > 50 ml/min; not recommended if eGFR < 50 ml/min. Source: Ilanne-Parikka P, Niskanen L, Rönnemaa T, Saha M-T (Eds.). Diabetes. Kustannus Oy Duodecim (Duodecim Publishing Company Ltd) 2019. Summaries of product characteristics August 2022: Terveysportti health portal / Duodecim lääketietokanta [Duodecim pharmaceutical database].(in Finnish) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other renal problems in people with diabetes
References
|